< Back to latest news & events

HGF Presents

Providing Enabling Disclosure for AI inventions at the EPO

September 2025

 

Video overview:

The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications to be challenged at the EPO. This is important to bear in mind when first drafting a patent application, because it cannot be resolved by later amendment or addition to the application. The core invention of AI-related patent application often lies in the practical implementation to solve a real-world problem It’s therefore not uncommon for AI inventions to be claimed as a “black box” and this can cause problems at the EPO. There is a growing body of appeal cases at the EPO Boards of Appeal which have ended with refusal of an AI-related patent application for sufficiency. The EPO Guidelines have been updated and appear to be more lenient than the body of appeal cases suggests. Our advice based on this is to describe at least one embodiment in enough detail which would enable a skilled person to build, train and implement the machine learning aspect of an invention.

Latest updates

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article

Precision Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Read article

Novelty Over Clinical Trials at the EPO

Video overview: Second medical use claims can be novel over clinical trials in European patents.  Typically, such a claim would be fairly narrow, e.g. perhaps mapping onto specific indications and …

Read article

Regulatory Exclusivity for
Medicinal Products in Europe

Video overview: New Medical Products 8 years of data exclusivity, followed by 2 years of market exclusivity. +1 year market exclusivity possible for a new indication showing significant clinical benefit. No exclusivity granted for new formulations or routes of …

Read article

Added Matter - Part 2

Video overview: Pre- and Post-Grant Amendments are governed by Articles 123(2) & 123(3) EPC respectively Before grant, amendments can broaden the claim scope as long as the resulting claim is …

Read article

Added Matter - Part 1

Video overview: What is Added Matter? Added matter occurs when an amendment introduces content that goes beyond what was originally disclosed in the application as filed (Article 123(2) EPC). EPO …

Read article